Literature DB >> 2992356

Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals.

C Prior, B Lang, D Wray, J Newsom-Davis.   

Abstract

We have studied the electrophysiological effects of IgG obtained from four patients with Lambert-Eaton myasthenic syndrome (LEMS) (two with small cell carcinoma), using the mouse passive transfer model. Mice received LEMS or control IgG or plasma, 10 to 60 mg daily. Microelectrode intracellular recordings were made from diaphragm muscle. LEMS IgG and plasma decreased end-plate potential quantal content similarly, confirming IgG as the active factor. LEMS IgG was equally effective in C5-deficient mice, indicating that late complement components are not required. The time course of decline and recovery of quantal content closely followed that of the human IgG in the mouse serum, with time to half-maximal effect of about 1.5 days in each case. Binding/dissociation of IgG or down/up regulation of the antigenic determinants, possibly Ca2+ channels, has a half-life of between 2 and 36 hours. The results confirm our concept that IgG antibody to nerve terminal determinants underlies the disorder of transmitter release in LEMS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992356     DOI: 10.1002/ana.410170610

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1985

3.  A neuromuscular transmission disorder: combined myasthenia gravis and Lambert Eaton syndrome in one patient.

Authors:  M J Taphoorn; H Van Duijn; E C Wolters
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

4.  Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line.

Authors:  C Peers; B Lang; J Newsom-Davis; D W Wray
Journal:  J Physiol       Date:  1990-02       Impact factor: 5.182

5.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

Authors:  S A Waterman
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

6.  Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.

Authors:  Michael T Flink; William D Atchison
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

Review 7.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

8.  The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse.

Authors:  B Lang; J Newsom-Davis; C Peers; C Prior; D W Wray
Journal:  J Physiol       Date:  1987-09       Impact factor: 5.182

Review 9.  Immunopathology of the Lambert-Eaton myasthenic syndrome.

Authors:  B Lang; J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1995

Review 10.  Autoimmune synaptopathies.

Authors:  Sarah J Crisp; Dimitri M Kullmann; Angela Vincent
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.